KR101732720B1 - A composition for anti-tussive activity or discharge of phlegm activity comprising of lonicera japonica, scutellaria baicalensis and liriopis tuber - Google Patents

A composition for anti-tussive activity or discharge of phlegm activity comprising of lonicera japonica, scutellaria baicalensis and liriopis tuber Download PDF

Info

Publication number
KR101732720B1
KR101732720B1 KR1020140140740A KR20140140740A KR101732720B1 KR 101732720 B1 KR101732720 B1 KR 101732720B1 KR 1020140140740 A KR1020140140740 A KR 1020140140740A KR 20140140740 A KR20140140740 A KR 20140140740A KR 101732720 B1 KR101732720 B1 KR 101732720B1
Authority
KR
South Korea
Prior art keywords
activity
composition
hae
extract
present
Prior art date
Application number
KR1020140140740A
Other languages
Korean (ko)
Other versions
KR20160045355A (en
Inventor
조형권
김혜수
김성연
전기용
전창현
장보윤
김대성
변에리사
유진주
김효진
김정영
Original Assignee
유한회사한풍제약
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유한회사한풍제약 filed Critical 유한회사한풍제약
Priority to KR1020140140740A priority Critical patent/KR101732720B1/en
Publication of KR20160045355A publication Critical patent/KR20160045355A/en
Application granted granted Critical
Publication of KR101732720B1 publication Critical patent/KR101732720B1/en

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/35Caprifoliaceae (Honeysuckle family)
    • A61K36/355Lonicera (honeysuckle)
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105Plant extracts, their artificial duplicates or their derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/53Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/539Scutellaria (skullcap)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/896Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/10Expectorants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/14Antitussive agents
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00Function of food ingredients
    • A23V2200/02Antioxidant
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00Function of food ingredients
    • A23V2200/30Foods, ingredients or supplements having a functional effect on health
    • A23V2200/314Foods, ingredients or supplements having a functional effect on health having an effect on lung or respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30Extraction of the material
    • A61K2236/33Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

본 발명은 인동등, 황금 및 맥문동 혼합 추출물을 유효성분으로 함유하는 진해 또는 거담용 조성물에 관한 것이다.
더욱 상세하게는, 인동등 1~5 중량부, 황금 0.5~1.5 중량부 및 맥문동 0.5~1.5 중량부로 혼합되며, 에탄올 또는 초산이 3% 함유된 에탄올을 용매로 사용하여 추출되는, 인동등, 황금 및 맥문동의 혼합 추출물을 유효성분으로 함유하는 진해 또는 거담용 조성물에 관한 것이다.
본 발명에 따른 조성물은 객담 배출능, 기침 억제능 및 항산화 효능을 보유하고 있다.
The present invention relates to a composition for deep sea or dandruff containing, as an active ingredient,
More particularly, the present invention relates to a process for producing a fermented soybean oil, which comprises 1 to 5 parts by weight of potash, 0.5 to 1.5 parts by weight of gold and 0.5 to 1.5 parts by weight of iron powder and extracted with ethanol containing 3% And a mixed extract of ginseng root as an active ingredient.
The composition according to the present invention has sputum-releasing ability, cough suppressing ability and antioxidant efficacy.

Description

인동등, 황금 및 맥문동 혼합 추출물을 유효성분으로 함유하는 진해 또는 거담용 조성물{A COMPOSITION FOR ANTI-TUSSIVE ACTIVITY OR DISCHARGE OF PHLEGM ACTIVITY COMPRISING OF LONICERA JAPONICA, SCUTELLARIA BAICALENSIS AND LIRIOPIS TUBER}FIELD OF THE INVENTION [0001] The present invention relates to a composition for a deep sea or a dandruff containing an extract of gold and mulberry leaves as an active ingredient,

본 발명은 인동등, 황금 및 맥문동 혼합 추출물을 유효성분으로 함유하는 진해 또는 거담용 조성물에 관한 것이다. The present invention relates to a composition for deep sea or dandruff containing, as an active ingredient,

더욱 상세하게는, 인동등 1~5 중량부, 황금 0.5~1.5 중량부 및 맥문동 0.5~1.5 중량부로 혼합되며, 에탄올 또는 초산이 0.5~5 % 함유된 에탄올을 용매로 사용하여 추출되는, 인동등, 황금 및 맥문동의 혼합 추출물을 유효성분으로 함유하는 진해 또는 거담용 조성물에 관한 것이다. More particularly, the present invention relates to a process for producing a fermented soybean oil, which is extracted with 1 to 5 parts by weight of potato, 0.5 to 1.5 parts by weight of gold and 0.5 to 1.5 parts by weight of corn sweet potato, using ethanol containing 0.5 to 5% , A mixture of gold and ginseng root as an active ingredient.

본 발명에 따른 조성물은 객담 배출능, 기침 억제능 및 항산화 효능을 보유하고 있다.
The composition according to the present invention has sputum-releasing ability, cough suppressing ability and antioxidant efficacy.

우리 몸의 호흡기는 물리 화학적인 외부 자극에 대한 방어 기관의 하나로써 급속한 산업화로 인한 대기오염 및 환경변화로 인해 호흡기질환 환자가 급증하고 있다. The respiratory system of our body is one of the defense institutions against the physicochemical external stimuli, and the respiratory disease patients are rapidly increasing due to the air pollution and environmental change due to rapid industrialization.

외부 자극물질이 호흡기로 유입되면 일차적으로 코털에 의해 걸러지며, 이를 통과한 미세 자극물질은 점액에 포획되어 섬모 운동을 통해 밖으로 배출되어 진다.
When the external stimulant enters the respiratory tract, it is primarily filtered by the nostrils, and the micro-stimulant that has passed through it is captured by the mucus and released through the ciliary movement.

기침은 점막 자극에 의한 반사적 방어기전으로 지나친 자극이나 지속적인 자극에 의한 지나친 기침은 환자의 삶의 질을 낮추고 기관지의 손상을 가속시킨다.Coughs are caused by mucous membrane stimulation and excessive coughing by excessive irritation or continuous irritation before the reflexive defense mechanism lowers the quality of life of the patient and accelerates the damage of the bronchial tubes.

또한 객담의 경우 외부 유입물질이 타액 또는 점액 물질과 함께 외부로 배출되는데 기관지 염증에 의해 화농성 객담이 발생하게 된다.
In addition, in the case of sputum, exogenous substances are released to the outside together with saliva or mucus material, and purulent sputum is generated by bronchial inflammation.

이러한 증상에 사용되는 의약품 중 진해제로 사용되고 있는 성분은 디하이드로코데인, 메틸에페드린, 클로로페닐라민, 덱스트로메트로판으로 중추신경에 작용하는 것들이다. Among the medicines used for these symptoms, dihydrocodeine, methylphedrine, chlorophenylamine, and dextromethorphan act on the central nervous system.

이러한 성분들은 심혈관계 혈전반응으로 인한 심근경색, 호흡억제, 위 또는 장출혈과 같은 부작용을 나타낸다. These components exhibit side effects such as myocardial infarction, respiratory depression, stomach or intestinal bleeding due to cardiovascular thrombosis.

검담제의 경우 아세틸시스테인, 엘도스테인, 카르보시스테인과 같은 치올계와 암브록솔과 같은 비치올계 거담제가 무분별하게 사용되고 있다.
Chrysanthemums such as acetylcysteine, eldostaine, carbostein, etc., are used indiscriminately in the case of insecticides.

따라서 보다 안전성이 확보된 천연물을 활용하여 진해거담제를 개발하고자 많은 연구가 진행되고 있으며, 본 발명에서는 인동, 황금 및 맥문동의 진해/거담 활성을 확인한 결과, 증상을 개선시키는 효능을 확인하여 본 발명을 완성하였다.
Therefore, much research has been conducted to develop a broad-leavening expectorant using safer natural materials. In the present invention, as a result of confirming the activity of shinhae / Completed.

인동(忍冬)은 인동과(Caprifoliaceae)에 속하는 인동덩굴(Lonicera Japonica Thunberg)의 잎 및 덩굴성 줄기를 말하며, 인동등(忍冬藤, Lonicera leaf and stem)이라고도 하고, 해열, 해독, 이뇨약으로서 임질, 소변불리, 근골동통 등의 치료약으로 사용되었다.
It is also known as Lonicera leaf and stem. It is also known as Lonicera Japonica Thunberg, which belongs to the genus Caprifoliaceae. , Urine discomfort, and muscle pain.

황금(黃芩)은 꿀풀과에 속한 다년생 초본인 황금(Scutellaria baicalensis Georgi)의 뿌리로써 청열조습(淸熱燥濕), 사화해독(瀉火解毒) 등의 효능이 있다.
Golden (黃 芩) is a perennial plant belonging to the family Lamiaceae ( Scutellaria baicalensis Georgi) has the efficacy as the roots of cheonggyu (淸 热 燥 濕) and poisoning (泻火 解毒).

맥문동(Liriopis Tuber)은 백합과(Liliaceae)에 속한 다년생 초본인 맥문동(Liriope platyphylla Wang et Tang) 또는 소엽맥문동(Ophiopogon japonicus Ker-Gawler)의 뿌리의 팽대부이다. Liriopis tuber is the bulge of the root of Liriope platyphylla Wang et Tang or Ophiopogon japonicus Ker-Gawler, a perennial herb belonging to Liliaceae.

성분으로는 steroid계 saponin, isoflavonoid, oligosaccharides 및 polysaccharide 등이 함유되어 있다. The ingredients include steroid saponin, isoflavonoid, oligosaccharides and polysaccharide.

맥문동은 혈당강하작용, 항염작용, IgM 항체생산 억제작용 등이 보고되어 있다.
McMundong has been reported to have hypoglycemic, anti-inflammatory, and anti-IgM antibody production.

한편, 본 발명과 관련된 선행기술로는 등록특허공보 제10-1367803호에 기관지염 치료를 위하여 마황을 포함하는 제약조성물 및 이를 만드는 제조방법에 대하여 기재되어 있다.
On the other hand, as a prior art related to the present invention, Patent Publication No. 10-1367803 discloses a pharmaceutical composition containing mahwang for treating bronchitis and a manufacturing method of the same.

상기 선행기술은 마황, 석고, 연교, 황금, 상백피, 행인, 전호, 반하, 청피, 절패모, 우방자, 금은화, 대황, 길경근 및 감초 등을 포함하고 있으며, 상기 제약조성물은 기침을 완화시키고, 가래를 없애며, 천식을 가라앉히고, 염증을 방지하는 데 유용한 효과가 있다.
The pharmaceutical composition of the present invention is a composition which alleviates coughing and alleviates coughing, and is effective for preventing cough, , Asthma is calmed down, and there is an effect useful in preventing inflammation.

그러나 상기 선행기술은 소재를 각각 추출한 후, 혼합하여 사용하므로 소재의 혼합 추출에 따른 효과를 알 수 없는 문제점이 있다.
However, the prior art has a problem in that the effect of mixed extraction of the material is unknown because the material is extracted and mixed after each extraction.

또한 상기 선행기술은 마황, 연교, 황금, 행인, 반하, 우방자 및 대황은 에탄올 추출하고 있으며, 석고, 상백피, 전호, 청피, 금은화, 길경근 및 감초는 물로만 추출하고 있으므로, 추출용매의 종류에 따른 추출물의 기관지염에 대한 효능은 알 수 없는 문제점이 있다.
In addition, since the above-mentioned prior art extracts ethanol from Mahwang, Kwanghwang, Kwangyang, Golden, passerby, Vanilla, Wisteria and Rhubarb, and extracts only ginseng with gypsum, The efficacy of the extract on bronchitis is unknown.

본 발명과 관련된 또 다른 선행기술로 등록특허공보 제10-0566542호에 알레르기성 비염과 감기의 예방 및 치료용 건강식품조성물 및 그 제조 방법이 기재되어 있다.Another prior art related to the present invention is disclosed in Korean Patent Registration No. 10-0566542, which discloses a health food composition for the prevention and treatment of allergic rhinitis and cold and a method for producing the same.

상기 선행기술은 유효성분으로 유근피, 진피, 감초, 오미자, 황기, 의이인, 어성초, 삼백초, 계지, 맥문동, 박하, 황금 및 백출을 함유하고 있으며, 재채기, 비즙, 비폐색 등을 포함하는 알레르기 비염의 증상개선에 있어서, 탁월한 치료효과가 있는 것을 특징으로 하고 있다.
The above-mentioned prior arts include symptoms of allergic rhinitis including active ingredients such as rhizomes, dandruff, licorice, omija, hwanggi, It is characterized in that it has an excellent therapeutic effect in improvement.

그러나 상기 선행기술은 알레르기 환자를 대상으로 한 임상 증상만을 관찰하였을 뿐, 입증된 방법을 통하여 실험을 수행하지 않았기 때문에, 조성물의 거담 활성 또는 진해 활성 등에 대한 효능을 객관적으로 평가할 수 없는 문제점이 있다.
However, since the above-described prior art only observes clinical symptoms for allergic patients, it has not been able to objectively evaluate the efficacy of the composition on dandruff activity or vigorous activity because the experiment is not conducted through the proven method.

또한 상기 선행기술은 열수 추출방법만을 이용하여 추출하고 있기 때문에, 추출용매의 종류에 따른 추출물의 효능은 알 수 없는 문제점이 있다.
In addition, since the prior art is extracted using only the hot water extraction method, there is a problem that the efficacy of the extract according to the type of the extraction solvent is unknown.

대한민국 등록특허공보 제10-1367803호 (2014.02.12)Korean Registered Patent No. 10-1367803 (Feb. 대한민국 등록특허공보 제10-0566542호 (2006.03.24)Korean Registered Patent No. 10-0566542 (Mar. 24, 2006)

본 발명에서 해결하고자 하는 과제는 인동등, 황금 및 맥문동 혼합 추출물을 유효성분으로 함유하는 진해 또는 거담용 조성물을 제공하는 데에 있다.A problem to be solved by the present invention is to provide a composition for deep sea or dandruff containing, as an active ingredient, a mixed extract of golden and mulberry leaves, such as indigo.

본 발명에서 해결하고자 하는 과제는 인동등 1~5 중량부, 황금 0.5~1.5 중량부 및 맥문동 0.5~1.5 중량부로 혼합되며, 에탄올 또는 초산이 0.5~5 % 함유된 에탄올을 용매로 사용하여 추출되는, 인동등, 황금 및 맥문동의 혼합 추출물을 유효성분으로 함유하는 진해 또는 거담용 조성물을 제공하는 데에 있다.The problem to be solved by the present invention is to provide a process for producing a fermented soybean milk, which comprises mixing 1 to 5 parts by weight of potato, 0.5 to 1.5 parts by weight of gold and 0.5 to 1.5 parts by weight of corn germ oil, and extracting using ethanol containing 0.5 to 5% , Rhizome, and the like, and a mixed extract of gold and marshmallow as an active ingredient.

본 발명에서 해결하고자 하는 과제는 객담 배출능, 기침 억제능 및 항산화 효능을 보유하는 진해 또는 거담용 조성물을 제공하는 데에 있다.
A problem to be solved by the present invention is to provide a composition for deep sea or dwarf, which has sputum-releasing ability, cough suppressing ability and antioxidant efficacy.

본 발명에서 해결하고자 하는 과제는 인동등, 황금 및 맥문동 혼합 추출물을 유효성분으로 함유하는 진해 또는 거담용 조성물을 제공하는 데에 있다.A problem to be solved by the present invention is to provide a composition for deep sea or dandruff containing, as an active ingredient, a mixed extract of golden and mulberry leaves, such as indigo.

본 발명에서 해결하고자 하는 과제는 인동등 1~5 중량부, 황금 0.5~1.5 중량부 및 맥문동 0.5~1.5 중량부로 혼합되며, 에탄올 또는 초산이 0.5~5 % 함유된 에탄올을 용매로 사용하여 추출되는, 인동등, 황금 및 맥문동의 혼합 추출물을 유효성분으로 함유하는 진해 또는 거담용 조성물을 제공하는 데에 있다.The problem to be solved by the present invention is to provide a process for producing a fermented soybean milk, which comprises mixing 1 to 5 parts by weight of potato, 0.5 to 1.5 parts by weight of gold and 0.5 to 1.5 parts by weight of corn germ oil, and extracting using ethanol containing 0.5 to 5% , Rhizome, and the like, and a mixed extract of gold and marshmallow as an active ingredient.

본 발명에서 해결하고자 하는 과제는 객담 배출능, 기침 억제능 및 항산화 효능을 보유하는 진해 또는 거담용 조성물을 제공하는 데에 있다.
A problem to be solved by the present invention is to provide a composition for deep sea or dwarf, which has sputum-releasing ability, cough suppressing ability and antioxidant efficacy.

본 발명에 따른 인동등, 황금 및 맥문동의 혼합 추출물을 유효성분으로 함유하는 진해 또는 거담용 조성물은 객담 배출능이 뛰어난 효능을 보유하고 있다.The composition for deep sea or dandruff containing the mixed extract of golden and mulberry leaves as an active ingredient according to the present invention has an excellent efficacy against sputum.

본 발명에 따른 인동등, 황금 및 맥문동의 혼합 추출물을 유효성분으로 함유하는 진해 또는 거담용 조성물은 기침 억제능이 뛰어난 효능을 보유하고 있다.The composition for deep sea or dandruff containing the mixed extract of golden and mulberry leaves as an active ingredient according to the present invention has an excellent effect of inhibiting cough.

본 발명에 따른 인동등, 황금 및 맥문동의 혼합 추출물을 유효성분으로 함유하는 진해 또는 거담용 조성물은 항산화 활성이 뛰어난 효능을 보유하고 있다.
The composition for deep sea or dandruff containing the mixed extract of golden and mulberry leaves as an active ingredient according to the present invention has an excellent antioxidant activity.

도 1은 혼합 추출물의 객담 배출능을 나타낸 것으로, 배출된 페놀의 농도를 측정한 그래프이다.
도 2는 혼합 추출물의 기침 억제능을 나타낸 것으로, 5초 동안 발생한 기침횟수를 측정한 그래프이다.
도 3은 혼합 추출물들의 항산화 효과를 나타낸 그래프로서, 흡광도를 %로 환산하여 나타낸 그래프이다.
FIG. 1 shows the sputum-releasing activity of the mixed extract, which is a graph measuring the concentration of the released phenol.
FIG. 2 is a graph showing the cough suppressing ability of the mixed extract, which is a measurement of the number of coughs occurring for 5 seconds.
FIG. 3 is a graph showing the antioxidative effect of the mixed extracts, and is a graph showing the absorbance in terms of%.

본 명세서 및 청구범위에 사용된 용어나 단어는 통상적이거나 사전적인 의미로 한정해서 해석되어서는 안 되며, 발명자는 그 자신의 발명을 가장 최선의 방법으로 설명하기 위해 용어의 개념을 적절하게 정의할 수 있다는 원칙에 입각하여 본 발명의 기술적 사상에 부합하는 의미와 개념으로 해석되어야만 한다.
The terms and words used in the present specification and claims should not be construed as limited to ordinary or dictionary terms and the inventor may properly define the concept of the term in order to best describe its invention It should be construed as meaning and concept consistent with the technical idea of the present invention.

따라서 본 명세서에 기재된 실험예와 참고예는 본 발명의 가장 바람직한 일실시예에 불과한 뿐이고 본 발명의 기술적 사상을 모두 대변하는 것은 아니므로, 본 출원시점에 있어서 이들을 대체할 수 있는 다양한 균등물과 변형예들이 있을 수 있음을 이해하여야 한다.
Therefore, the experimental examples and the reference examples described in the present specification are merely the most preferred embodiments of the present invention and are not intended to represent all of the technical ideas of the present invention. Therefore, various equivalents and variations Examples should be understood.

실시예Example 1.  One. 인동등Incandescent light , 황금 및 맥문동 혼합 추출물(, Golden and Mantum Dong mixed extract ( HAEHAE -03)의 제조-03)

인동등, 황금 및 맥문동은 1~5 : 0.5~1.5 : 0.5~1.5 중량부로 혼합되어 추출될 수 있다. 바람직하게는 2.5~3.5 : 1 : 1의 중량부로 혼합하여 사용할 수 있다.
And rhododendron can be mixed and extracted at 1 to 5: 0.5 to 1.5: 0.5 to 1.5 parts by weight. Preferably 2.5 to 3.5: 1: 1, by weight.

추출 방법은 이산화탄소 초임계 추출법, 수증기 증류법, 진공추출법, 감압추출법, 마이크로 웨이브 공정 추출법, 퍼콜레이션 추출법 등의 다양한 추출 방법이 사용될 수 있으나, 바람직하게는 용매 추출법이 사용될 수 있다.
Various extraction methods such as a carbon dioxide supercritical extraction method, a steam distillation method, a vacuum extraction method, a vacuum extraction method, a microwave process extraction method, and a percolation extraction method may be used, but a solvent extraction method may be preferably used.

추출에 사용되는 용매는 물, 에탄올, 메탄올, 지방유, 글리세린, 마유, 플로필렌글리콜, 에테르, 클로르포름, 석유에테르, 헥산, 벤젠, 메틸렌클로라이드, 에틸아세테이트, 아세톤, 부탄올, 이소프로판올, 액체암모니아, 삼염화안티몬 및 불화수소 등에서 선택될 수 있다.
The solvent used for the extraction is selected from the group consisting of water, ethanol, methanol, fatty oil, glycerin, hemp, flouropylene glycol, ether, chloroform, petroleum ether, hexane, benzene, methylene chloride, ethyl acetate, acetone, butanol, isopropanol, Antimony, hydrogen fluoride and the like.

바람직한 추출방법으로는 소재를 혼합한 후, 30%(v/v) 에탄올 수용액을 10배수 넣고 80~90℃로 3시간 환류냉각 추출한 후 여과하여 1차 추출액을 얻을 수 있다.
As a preferred extraction method, the materials are mixed, and then 10% aqueous solution of 30% (v / v) ethanol is added thereto, refluxed at 80 to 90 ° C for 3 hours and then filtered to obtain a primary extract.

잔사를 1차 추출방법과 동일하게 반복 추출한 다음 추출액을 60℃ 이하에서 감압농축 하고 진공건조 하여 건조엑스를 얻음으로써, 인동등, 황금 및 맥문동 혼합 추출물을 제조할 수 있다.
The residue is repeatedly extracted in the same manner as in the first extraction method, and then the extract is concentrated under reduced pressure at 60 ° C or lower and vacuum dried to obtain a dried extract, whereby a golden and mulberry root mixed extract can be prepared.

실시예Example 2.  2. 인동등Incandescent light , 황금 및 맥문동 혼합 추출물(, Golden and Mantum Dong mixed extract ( HAEHAE -04)의 제조-04)

실시예 1에 따른 방법과 동일하게 수행하되, 추출 용매를 30%(v/v) 에탄올 수용액에서, 3%(v/v) 초산이 포함된 30%(v/v) 에탄올 수용액으로 변경하여 추출한다.
(V / v) aqueous solution of ethanol containing 3% (v / v) acetic acid in 30% (v / v) do.

실시예 1 및 2에 따른 인동등, 황금 및 맥문동 혼합 추출물의 효능을 평가하기 위해, 인동등, 황금 및 길경 혼합 추출물을 제조하여 함께 비교하였다.
In order to evaluate the efficacy of the golden and manganese mixed extracts such as potatoes according to Examples 1 and 2, the extracts of golden and Gyungyang were prepared and compared together.

비교예Comparative Example 1.  One. 인동등Incandescent light , 황금 및 , Gold and 길경Gakyung 혼합 추출물( Mixed extract ( HAEHAE -01)의 제조 -01)

인동등 120 g, 황금 40 g, 길경 40 g을 넣고 30%(v/v) 에탄올 수용액을 10배수 넣고 80~90℃로 3시간 환류냉각 추출한 후 여과하여 1차 추출액을 얻는다. 40 g of gold and 40 g of gypsum and put in 10 volume of 30% (v / v) ethanol solution, reflux cooled for 3 hours at 80 ~ 90 ℃ and then filtered to obtain a primary extract.

잔사를 1차 추출방법과 동일하게 반복 추출한 다음 추출액을 60℃ 이하에서 감압농축 하고 진공건조 하여 건조엑스 약 57.6 g(수율 28.80%)을 얻는다.
The residue is repeatedly extracted in the same manner as in the first extraction method. The extract is concentrated under reduced pressure at 60 ° C or lower and vacuum dried to obtain about 57.6 g (yield: 28.80%) of dried extract.

비교예Comparative Example 2.  2. 인동등Incandescent light , 황금 및 , Gold and 길경Gakyung 혼합 추출물( Mixed extract ( HAEHAE -02)의 제조-02)

인동등 120 g, 황금 40 g, 길경 40 g을 넣고 3%(v/v) 초산이 포함된 30%(v/v) 에탄올 수용액을 10배수 넣고 80~90℃로 3시간 환류냉각 추출한 후 여과하여 1차 추출액을 얻는다. (V / v) aqueous ethanol solution containing 3% (v / v) acetic acid was added to 10 g of water, reflux cooled for 3 hours at 80 to 90 ° C., To obtain a primary extract.

잔사를 1차 추출방법과 동일하게 반복 추출한 다음 추출액을 60℃ 이하에서 감압농축 하고 진공건조 하여 건조엑스 약 53.5 g(수율 26.75%)을 얻는다.
The residue is repeatedly extracted in the same manner as in the first extraction method. The extract is concentrated under reduced pressure at 60 ° C or lower and vacuum dried to obtain about 53.5 g (yield: 26.75%) of dried extract.

실험예Experimental Example 1. 거담 활성 평가 1. Evaluation of gadam activity

1-1. 실험 과정1-1. Experimental course

제조된 혼합 추출물의 거담 활성을 평가하기 위하여, Engler 등의 방법을 이용하여(Engler H, Szelenyi I, J.Pharmacol. Moth.11,151~157,1984., Bao-quin Lin et., Pulmonary Pharmacology & Therapeutics 21, 259~263, 2008.) 평가 실험을 수행하였다. 실험과정은 다음과 같다.
(Engler H, Szelenyi I, J. Pharmacol. Moth., 151 ~ 157, 1984, Bao-quin Lin et al., Pulmonary Pharmacology & Therapeutics 21, 259-263, 2008.) Evaluation experiments were conducted. The experimental procedure is as follows.

① 양성대조약물(암브록솔, ambroxol, Sigma), 시험약물을 수컷랫트(6주령, 샘타코 바이오코리아)에 경구 투여하고 30분 후, 페놀레드를 복강주사 하였다(200 mg/kg 용량으로 투여하며, 페놀레드는 생리식염수에 녹여서 사용함). The test compound was orally administered to male rats (6 weeks old, Sumatoco Bio Korea) for 30 minutes, and the test compound was intraperitoneally injected with phenol red (200 mg / kg dose) And phenol red dissolved in physiological saline).

② 30분 후 디에틸에테르를 이용해 마취시키고 복부 대동맥을 절단하여 방혈시킨 후, 기관 (trachea) 전체를 절제하였다. ② After 30 minutes, anesthesia was performed with diethyl ether, and the abdominal aorta was cut to bleed, and then the entire trachea was excised.

③ 분리된 기관을 1 ml의 생리 식염수에 넣어 30 분 동안 세척하였고, 10,000 rpm으로 5분간 상온에서 원심분리하여 얻은 상등액에 1 N 가성소다 (NaOH)를 첨가 (상등액 1 ml당 1N NaOH 0.1 ml 첨가)하였다. ③ Separated organs were washed in 1 ml of physiological saline for 30 minutes and centrifuged at 10,000 rpm for 5 minutes at room temperature. 1 N sodium hydroxide (NaOH) was added to the supernatant (0.1 ml of 1N NaOH per 1 ml of supernatant ).

④ 이들에 대한 546 nm에서의 흡광도를 측정하여 배출된 페놀레드의 농도로서 거담활성을 평가하였다.
(4) The absorbance at 546 nm was measured to evaluate the drought activity as the concentration of the phenol red discharged.

1-2. 실험 결과1-2. Experiment result

아래 [표 1]은 양성대조약물로 사용된 암브록솔과 제조된 혼합 추출물의 투여 용량에 따른 객담 배출능을 나타낸 표이다.
Table 1 below is a table showing the sputum-releasing ability according to the administration dose of ambroxol used as a positive control drug and the mixed extract prepared.

구분division 투여용량(mg/kg)Dosage (mg / kg) 객담 배출능(%)Sputum Emission Rate (%) HAE-01HAE-01 200200 1717 HAE-02HAE-02 200200 3030 HAE-03HAE-03 200200 2222 HAE-04HAE-04 200200 6666 암브록솔(Ambroxol)Ambroxol 250250 9191

실험 결과, 인동등, 황금 및 길경 에탄올 추출물(HAE-01)에 비해 인동등, 황금 및 맥문동 에탄올 추출물(HAE-03)의 객담 배출능이 높은 것을 알 수 있으며, 인동등, 황금 및 길경의 초산 3% 함유 에탄올 추출물(HAE-02)에 비해, 인동등, 황금 및 맥문동의 초산 3% 에탄올 추출물(HAE-04)의 객담 배출능이 높은 것을 알 수 있다.
The results showed that the ethanol extract (HAE-03) of golden and mangmundong ethanol extracts (Hae-gyeong) had a higher sputum emission ability than the ethanol extract of Haengdong et al. (HAE-01) (HAE-04) of acetic acid in golden and macromuscular ginsengs, such as potash, is higher than that of ethanol-containing ethanol extract (HAE-02).

따라서 동일한 방법과 용매로 추출하였지만, 인동등, 황금 및 길경 조합보다는 인동등, 황금 및 맥문동 조합의 추출물이 객담 배출능이 더욱 뛰어난 것을 알 수 있다. Therefore, it was found that the extracts of gold and mangmundong combination extracts of sponges were more excellent in sputum production ability than extracts of the same method and solvent.

또한 에탄올 추출물보다는 초산 3%가 함유된 에탄올 추출물의 객담 배출능이 더 뛰어난 것을 확인하였다.
In addition, ethanol extracts containing 3% acetic acid showed better sputum emission than ethanol extracts.

도 1은 혼합 추출물의 객담 배출능을 나타낸 것으로, 배출된 페놀의 농도를 측정한 그래프이다.
FIG. 1 shows the sputum-releasing activity of the mixed extract, which is a graph measuring the concentration of the released phenol.

실험 결과, 대조군에 비해 양성대조군인 암브록솔의 페놀 농도가 약 2배가량 증가한 것을 확인할 수 있다. As a result, it was confirmed that the concentration of amoxicillin phenol in the positive control group was about twice that of the control group.

HAE-01 내지 HAE-04 실험군에서는 대조군에 비해 페놀 농도가 증가한 것을 보여, 객담 배출능을 보유하고 있음을 알 수 있고, 특히 HAE-04 실험군(인동등, 황금 및 맥문동의 초산 3% 에탄올 추출물)의 경우 유의한 객담 배출능을 보이는 것을 확인하였다.
In the HAE-01 to HAE-04 experimental groups, the phenol concentration was increased compared to the control group, and it was found that they had sputum-releasing ability. Especially HAE-04 test group (3% Of the patients were found to have significant sputum production.

실험예Experimental Example 2. 진해 활성 평가 2. Evaluation of Chinhae activity

2-1. 실험 과정2-1. Experimental course

혼합 추출물에 대하여 진해 활성을 측정하기 위해, Tanaka 등의 방법을 이용하여(Motomu Tanaka and Kei Maruyama., J. Pharmacol.Sci. 93, 465~470, 2003., Daoui, Cognon, Naline et., Am. J. Respir. Crit. Care. Med. 158, 42~48, 1998.)평가하였다. 실험과정은 다음과 같다.
In order to measure the activity of the mixed extract, Tanaka et al. (Motomu Tanaka and Kei Maruyama, J. Pharmacol. Sci., 93, 465-470, 2003. Daoui, Cognon, Naline et. J. Respir. Crit Care, Med., 158, 42-48, 1998.). The experimental procedure is as follows.

① 수컷 ICR 마우스(6주령, 오리엔트바이오)에 약물을 경구투여하고 30분후 마우스를 플레티시스모그래프 챔버 (Buxco, U.S.A.)에 넣은 후, 기침 유발제 (시트르산)를 분무하여 기침을 유발시켰다.After 30 minutes of oral administration of the drug to a male ICR mouse (6 weeks old, Orient Bio), the mice were placed in a plexi-smear chamber (Buxco, USA) and cough induced by spraying a cough inducer (citric acid).

② 양성대조군으로는 진해제로 사용되고 있는 테오브로민(50 mg/kg)을 사용하였으며, 0.4 M의 시트르산에 마우스를 10분간 노출시키고 이때 발생하는 기침수를 5초 간격으로 10분간 측정하였다.
Theobromine (50 mg / kg) was used as a positive control, and mice were exposed to 0.4 M citric acid for 10 minutes, and the cough water generated was measured at intervals of 5 seconds for 10 minutes.

2-2. 실험 결과2-2. Experiment result

아래 [표 2]는 양성대조약물로 사용된 테오브로민과 제조된 혼합 추출물의 투여 용량에 따른 기침 억제능을 나타낸 표이다.
Table 2 below is a table showing cough inhibition according to the dose of theobromine used as a positive control drug and the mixed extract prepared.

구분division 두여용량(mg/kg)Dosage (mg / kg) 기침횟수/5초Coughing / 5 seconds 대조군Control group -- 2.44 ± 0.242.44 ± 0.24 HAE-01HAE-01 200200 2.55 ± 0.332.55 + - 0.33 HAE-02HAE-02 200200 2.67 ± 0.342.67 ± 0.34 HAE-03HAE-03 200200 2.47 ± 0.282.47 ± 0.28 HAE-04HAE-04 200200 2.53 ± 0.342.53 + - 0.34 테오브로민(Theobromine)Theobromine 5050 2.31 ± 0.172.31 ± 0.17

실험 결과, HAE-01, HAE-02 실험군에 비해, HAE-03 및 HAE-04 실험군의 기침횟수가 감소한 것을 확인하였다.
As a result, the number of coughs in the HAE-03 and HAE-04 test groups was reduced compared to the HAE-01 and HAE-02 test groups.

도 2는 혼합 추출물의 기침 억제능을 나타낸 것으로, 5초 동안 발생한 기침횟수를 측정한 그래프이다.
FIG. 2 is a graph showing the cough suppressing ability of the mixed extract, which is a measurement of the number of coughs occurring for 5 seconds.

도 2에서 보는 바와 같이, 대조군에 비해 테오브로민 처리군에서 기침횟수가 감소하는 것을 확인하였다. As shown in FIG. 2, it was confirmed that the number of coughs decreased in the theobromine-treated group compared to the control group.

또한 인동등, 황금 및 길경의 혼합 추출물에 비해 인동등, 황금 및 맥문동의 혼합 추출물이 기침횟수가 더욱 감소한 것을 확인하여, 기침 억제능이 더 뛰어난 것을 확인하였다.
In addition, it was confirmed that the number of coughs was further reduced by the mixed extract of golden and mackerel dung, such as indigo, compared with the mixed extract of gold and gyeongyang, such as indigo.

실험예Experimental Example 3. 항산화 활성 평가 3. Antioxidant activity evaluation

3-1. 실험 과정3-1. Experimental course

DPPH assay는 항산화 효능을 측정하는 실험 중 가장 보편적인 실험 중 하나이다. DPPH assay의 원리는 진한 보라색을 띠는 Diphenylpicrylhydrazyl이 항산화제에 의해 Diphenylpicrylhydrazine으로 환원되어 옅은 노란색으로 변하는 것으로, 항산화제의 항산화력이 강할 수록 옅은 노란색에 가까워진다.The DPPH assay is one of the most common experiments to measure antioxidant efficacy. The principle of DPPH assay is that the deep purple Diphenylpicrylhydrazyl is reduced to Diphenylpicrylhydrazine by the antioxidant and turns into a pale yellow. The stronger the antioxidant power of the antioxidant, the closer it is to the pale yellow.

또한 흡광도 측정시 짙은 보라색은 감지되나 옅은 노란색은 감지되지 못한다. 따라서 흡광도의 수치가 작게 나올수록 항산화력이 높은 것이라고 할 수 있다. 실험 과정은 다음과 같다.
Also, when measuring the absorbance, a dark purple color is detected but a light yellow color is not detected. Therefore, the smaller the absorbance value is, the higher the antioxidant power is. The experimental procedure is as follows.

① 0.1 mM DPPH 용액(Diphenylpicrylhydrazyl)을 8그룹 준비하였다. ① 8 groups of 0.1 mM DPPH solution (Diphenylpicrylhydrazyl) were prepared.

② 1 그룹은 음성 대조군으로 설정하여 어떤 조작도 하지 않았으며, 2그룹은 양성 대조군으로 설정하여 ascorbic acid(Vitamin C) 50 M을 처리하였다. ② Group 1 was set as negative control and no manipulation was performed. Group 2 was set as positive control and treated with ascorbic acid (Vitamin C) 50M.

③ 실험 그룹에는 추출물을 각각 10 g/mL, 30g/mL, 100 g/mL씩 처리하였다. ③ In the experiment group, the extracts were treated with 10 g / mL, 30 g / mL and 100 g / mL, respectively.

④ 520nm의 파장에서 흡광계를 이용하여 시료들의 색이 어떻게 변하는지 관찰하였다.④ We observed how the color of the samples changed using a light absorber at a wavelength of 520 nm.

⑤ 측정된 흡광도를 다음의 식으로 %환산하였다.
⑤ The measured absorbance was converted in% by the following equation.

Figure 112014099108477-pat00001
Figure 112014099108477-pat00001

3-2. 실험 결과3-2. Experiment result

다음 [표 3]은 혼합 추출물의 항산화 효능을 나타낸 것으로, 처리용량에 따른 항산화 효과를 나타낸 표이며, 도 3은 혼합 추출물들의 항산화 효과를 나타낸 그래프로서, 흡광도를 %로 환산하여 나타낸 그래프이다.
The following Table 3 shows the antioxidative effect of the mixed extracts. The antioxidative effect of the mixed extracts is shown in Table 3, and FIG. 3 is a graph showing the antioxidative effect of the mixed extracts.

구분division 처리용량(㎍/㎖)Treatment volume ([mu] g / ml) 항산화 효과(%)Antioxidative effect(%)
HAE-01

HAE-01
1010 12.112.1
3030 69.269.2 100100 48.848.8
HAE-02

HAE-02
1010 11.211.2
3030 72.172.1 100100 70.370.3
HAE-03

HAE-03
1010 9.89.8
3030 18.318.3 100100 69.469.4
HAE-04

HAE-04
1010 17.317.3
3030 72.272.2 100100 72.572.5 Vitamin CVitamin C 50 μM50 μM 76.376.3

실험 결과, 모든 혼합 추출물에서 음성 대조군과 비교했을 때 농도 의존적인 항산화 효과를 나타내었다. As a result of the experiment, all of the mixed extracts showed a concentration-dependent antioxidative effect as compared with the negative control group.

Claims (5)

인동등, 황금 및 맥문동의 혼합 추출물을 유효성분으로 함유하는 진해 또는 거담용 약학 조성물에 있어서,
상기 혼합 추출물은,
인동등 1~5 중량부, 황금 0.5~1.5 중량부 및 맥문동 0.5~1.5 중량부로 혼합되어 추출되되,
에탄올 또는 초산이 0.5~5 % 함유된 에탄올을 용매로 사용하여 추출됨으로 써,
객담 배출능, 기침 억제능 및 항산화 효능을 보유하는 것을 특징으로 하는, 인동등, 황금 및 맥문동의 혼합 추출물을 유효성분으로 함유하는 진해 또는 거담용 약학 조성물.
Which comprises as an active ingredient, a mixed extract of gold and rhododendron,
The above-
0.5 to 1.5 parts by weight of gold and 0.5 to 1.5 parts by weight of copper powder,
By using ethanol containing 0.5 to 5% of ethanol or acetic acid as a solvent,
Wherein the extract has a sputum-releasing ability, a cough suppressing ability, and an antioxidant activity, as an active ingredient.
삭제delete 삭제delete 삭제delete 인동등, 황금 및 맥문동의 혼합 추출물을 유효성분으로 함유하는 진해 또는 거담용 건강기능식품 조성물.Which comprises as an active ingredient a mixed extract of golden and mulberry leaves.
KR1020140140740A 2014-10-17 2014-10-17 A composition for anti-tussive activity or discharge of phlegm activity comprising of lonicera japonica, scutellaria baicalensis and liriopis tuber KR101732720B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020140140740A KR101732720B1 (en) 2014-10-17 2014-10-17 A composition for anti-tussive activity or discharge of phlegm activity comprising of lonicera japonica, scutellaria baicalensis and liriopis tuber

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020140140740A KR101732720B1 (en) 2014-10-17 2014-10-17 A composition for anti-tussive activity or discharge of phlegm activity comprising of lonicera japonica, scutellaria baicalensis and liriopis tuber

Publications (2)

Publication Number Publication Date
KR20160045355A KR20160045355A (en) 2016-04-27
KR101732720B1 true KR101732720B1 (en) 2017-05-04

Family

ID=55914649

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020140140740A KR101732720B1 (en) 2014-10-17 2014-10-17 A composition for anti-tussive activity or discharge of phlegm activity comprising of lonicera japonica, scutellaria baicalensis and liriopis tuber

Country Status (1)

Country Link
KR (1) KR101732720B1 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102526467A (en) * 2012-02-15 2012-07-04 中国人民解放军第三军医大学第二附属医院 Chinese medicinal composition for treating pulmonary fungal infection and preparation method thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100566542B1 (en) 2004-04-20 2006-03-30 (주)바이오솔루션 A health food composition for prevention and treatment of allergic rhinitis and influenza and a method for preparation thereof
KR101367803B1 (en) 2012-09-18 2014-02-28 굿스틸뱅크 주식회사 Heater of metal fiber manufacturing apparatus

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102526467A (en) * 2012-02-15 2012-07-04 中国人民解放军第三军医大学第二附属医院 Chinese medicinal composition for treating pulmonary fungal infection and preparation method thereof

Also Published As

Publication number Publication date
KR20160045355A (en) 2016-04-27

Similar Documents

Publication Publication Date Title
Adam et al. Pharmacological properties of agarwood tea derived from Aquilaria (Thymelaeaceae) leaves: An emerging contemporary herbal drink
KR101346244B1 (en) Composition for preventing or relieving alcohol-induced hangover comprising medicinal herbs
Fierascu et al. Leonurus cardiaca L. as a source of bioactive compounds: an update of the European medicines agency assessment report (2010)
KR101286467B1 (en) A composition comprising mixed herbal extract of Cnidii Rhizoma and Undulatum Rhubarb for treating or preventing respiratory disease
Liu et al. Farfarae Flos: A review of botany, traditional uses, phytochemistry, pharmacology, and toxicology
Zheng et al. Research advances in lotus leaf as Chinese dietary herbal medicine
KR101619733B1 (en) A composition for anti-tussive activity or discharge of phlegm activity comprising of lonicera japonica, scutellaria baicalensis, adenophorea radix and polygonati odorati
CN105326888A (en) Medicinal composition for treating child phlegm-heat obstructing lung type asthma
KR101286463B1 (en) A composition comprising extract of Cnidii Rhizoma for treating or preventing respiratory disease
JP6712056B2 (en) Hepatocyte growth factor production inducer
KR101517833B1 (en) A composotion for the treatment of dyslipidemia comprising the red ginseng complex
KR101286465B1 (en) A composition comprising mixed herbal extract of Cnidii Rhizoma and Corydalis Tuber for treating or preventing respiratory disease
CN109239239B (en) Traditional Chinese medicine composition for clearing lung, eliminating phlegm, relieving cough and asthma and preparation method and application thereof
JP2015524813A (en) Application of Takasago Sanchisou to the manufacture of drugs for treating hepatitis or foods for health
KR101732720B1 (en) A composition for anti-tussive activity or discharge of phlegm activity comprising of lonicera japonica, scutellaria baicalensis and liriopis tuber
KR102557388B1 (en) Method for manufacturing hangover recovery agent and hangover recovery agent manufactured by the same
Barik et al. Management of asthma by herbal therapy with special reference to polyherbal formulation.
CN111419894A (en) Pharmaceutical composition for reducing uric acid and preparation method thereof
KR101647506B1 (en) Detoxifying methods for extracts of Coptidis Rhizoma, detoxified herbal extracts manufactured by the same, and composition comprising for preventing and treating a respiratory organ disease comprising the herbal extracts
Kaviya et al. Physiochemical analysis and phytochemical screening of ivy gourd, Coccinia grandis (L.) Voigt leaves
JP7407735B2 (en) A composition having antitussive and expectorant activity, comprising extracts of Schisandra and Schisandra
CN109453249B (en) Pharmaceutical composition for preventing and treating drug-induced liver injury and preparation method of different dosage forms
Akhil A pharmacological evaluation for the ethanolic extract of Alpinia Calcarata rhizome for it’s anti-asthmatic, antioxidant and anti-inflammatory activities
CN113101331B (en) Thyme herb tea and preparation method and application thereof
CN114931214B (en) Chinese herbal medicine composition for improving hearing impairment and preparation method and application thereof

Legal Events

Date Code Title Description
E601 Decision to refuse application
J201 Request for trial against refusal decision
J301 Trial decision

Free format text: TRIAL NUMBER: 2016101003754; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20160627

Effective date: 20170227

S901 Examination by remand of revocation
GRNO Decision to grant (after opposition)
GRNT Written decision to grant